, Tracking Stock Market Picks
Enter Symbol:
Rating: CVS
Overweight $110
up 27.00 %

CVS Corporation (NYSE: CVS) reiterated to Overweight with price target $110 by Barclays

Friday,  Dec 18, 2015  2:25 PM ET by Dave Ficere

Barclays reiterated CVS Corporation (NYSE: CVS) to Overweight with price target $110. Previously Barclays rated Overweight with price target $85 CVS Corporation (NYSE:
CVS) on 05/05/2014, when the stock price was $74.98. Since then, CVS Corporation's stock price has gained 27% as of 12/18/2015's recent price of $95.27.
If you would have followed the previous Barclays's recommendation on CVS, you would have gained 27% of your investment in 592 days.

CVS Caremark Corporation (CVS Caremark) is a provider of prescriptions and related healthcare services in the United States. It is a pharmacy services company and drives value for its customers through its approximately 6,900 CVS/pharmacy and Longs Drug retail stores; CVS Caremark?s pharmacy benefit management, mail order and specialty pharmacy division, Caremark Pharmacy Services; its retail-based health clinic subsidiary, MinuteClinic, and Its online pharmacy, The Company operates in two business segments: Pharmacy Services and Retail Pharmacy. October 20, 2008, CVS Caremark acquired Longs Drug Stores Corporation, which includes 529 retail drug stores (the Longs Drug Stores) and RxAmerica LLC (RxAmerica), which provides pharmacy benefit management services, and certain other related assets.


RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy